Date: 2014-06-10
Type of information: R&D agreement
Compound: novel hits against a disease-relevant protease
Company: Beactica (Sweden) Medivir (Sweden)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On June 10, 2014, Beactica, a Swedish fragment-based drug discovery company, announced that it has entered into an agreement with Medivir. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary discovery platform.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
